TABLE 3.
Risk factors for clinical failure of ceftazidime-avibactam therapy among patients with CRE infection
| Risk factora | Valueb for patients with: |
P value | Multivariate P value (OR, 95% CI)c | |
|---|---|---|---|---|
| Success (n = 42) | Failure (n = 35) | |||
| Demographics and underlying conditions | ||||
| Male gender | 29 (69) | 18 (51) | 0.16 | |
| Age (yr) | 64 (19–91) | 59 (26–79) | 0.22 | |
| Solid-organ transplant recipient | 9 (21) | 9 (26) | 0.79 | |
| Charlson Comorbidity Index | 4 (0–10) | 5 (0–10) | 0.86 | |
| Severity of illness | ||||
| ICU at disease onset | 17 (40) | 27 (77) | 0.001 | Excluded |
| Renal replacement therapy | 3 (7) | 13 (37) | 0.002 | 0.046 (4.78, 1.03–22.2) |
| SOFA score | 5 (0–18) | 8 (0–20) | 0.0007 | 0.13 |
| SAPS II score | 37 (8–62) | 43 (17–81) | 0.04 | 0.98 |
| Infection characteristics | ||||
| Infection type | ||||
| Pneumonia | 12 (29) | 21 (60) | 0.01 | 0.045 (3.09, 1.03–9.34) |
| Primary bacteremia | 15 (36) | 5 (14) | 0.04 | |
| Urinary tract infection | 7 (17) | 1 (3) | 0.07 | |
| Intra-abdominal infection | 3 (7) | 4 (11) | 0.70 | |
| Skin/soft tissue infection | 4 (10) | 2 (6) | 0.68 | |
| Other | 1 (2) | 2 (6) | 0.59 | |
| CRE pathogen | ||||
| K. pneumoniae | 34 (81) | 25 (71) | 0.42 | |
| E. coli | 5 (12) | 4 (11) | 1.00 | |
| E. cloacae | 2 (5) | 3 (9) | 0.65 | |
| Other | 2 (5) | 2 (6) | 1.00 | |
| Presence of blaKPC | ||||
| KPC-2 | 15 (36) | 7 (20) | 0.20 | |
| KPC-3 | 19 (45) | 17 (49) | 0.82 | |
| KPC negative | 8 (19) | 11 (31) | 0.29 | |
| Treatment characteristics | ||||
| Time to treatment initiation (h) | 71 (15–162) | 76 (3–168) | 0.87 | |
| Ceftazidime-avibactam monotherapy | 30 (71) | 23 (66) | 0.63 | |
a
Statistically significant risk factors for clinical failure of ceftazidime-avibactam are shown in boldface. ICU, intensive care unit.
b
Values for categorical variables are numbers (percentages) of patients with the risk factor. Values for continuous variables are medians (ranges).
c
OR, odds ratio; CI, confidence interval.